Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 Dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease

Ren, Q; Chen, Y; Zhou, ZT; Cai, ZY; Jiao, SX; Huang, WQ; Wang, B; Chen, SL; Wang, WX; Cao, ZJ; Yang, ZC; Deng, LM; Hu, LJ; Zhang, LY; Li, Z

Zhang, LY; Li, Z (通讯作者)，Guangdong Pharmaceut Univ, Sch Pharm, Evaluat Guangdong Prov Educ Dept, Key Lab New Drug Discovery, Guangzhou 510006, Peoples R China.;Zhang, LY (通讯作者)，China Pharmaceut Univ, Jiangsu Key Lab Drug Screening, Nanjing 210009, Peoples R China.;Li, Z (通讯作者)，First Affiliated Hosp Guangdong Pharmaceut Univ, Key Specialty Clin Pharm, Guangzhou 510006, Peoples R China.

JOURNAL OF MEDICINAL CHEMISTRY, 2023; 66 (9): 6082

Abstract

The prevalence of nonalcoholic steatohepatitis (NASH) is increasing rapidly worldwide, and NASH has become a serious problem for human health. Recentl......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索